Sulfacytine: Difference between revisions
CSV import |
CSV import |
||
| Line 25: | Line 25: | ||
{{Antibiotics-stub}} | {{Antibiotics-stub}} | ||
{{Medicine-stub}} | {{Medicine-stub}} | ||
== Sulfacytine == | |||
<gallery> | |||
File:Sulfacytine_v2.svg | |||
File:Sulfacytine_3D.png | |||
</gallery> | |||
Latest revision as of 02:03, 17 February 2025
Sulfacytine is a sulfonamide antibiotic used in the treatment of various bacterial infections. It is a synthetic derivative of para-aminobenzoic acid (PABA) and works by inhibiting the synthesis of folic acid in bacteria, thereby preventing their growth.
History[edit]
Sulfacytine was first synthesized in the 1930s, following the discovery of the antibacterial properties of Prontosil, the first sulfonamide antibiotic. It was one of many sulfonamides developed in an attempt to create a broad-spectrum antibiotic with fewer side effects.
Mechanism of Action[edit]
Sulfacytine, like other sulfonamides, is a competitive inhibitor of dihydropteroate synthase (DHPS), an enzyme involved in the synthesis of folic acid in bacteria. By mimicking the structure of PABA, a substrate of DHPS, sulfacytine is able to bind to the enzyme and prevent it from catalyzing the conversion of PABA to dihydropteroate, a precursor of folic acid. This inhibits the growth of bacteria by depriving them of the folic acid necessary for DNA synthesis.
Clinical Use[edit]
Sulfacytine is used in the treatment of a variety of bacterial infections, including urinary tract infections, respiratory tract infections, and skin infections. It is also used in combination with other antibiotics in the treatment of tuberculosis.
Side Effects[edit]
Common side effects of sulfacytine include nausea, vomiting, and diarrhea. In rare cases, it can cause serious side effects such as Stevens-Johnson syndrome, a severe skin reaction, and hemolytic anemia, a condition in which red blood cells are destroyed faster than they can be made.
Resistance[edit]
Resistance to sulfacytine and other sulfonamides has become increasingly common among many types of bacteria. This is often due to mutations in the gene encoding DHPS, which can alter the enzyme's structure and prevent sulfacytine from binding to it.
| This article is a stub. You can help WikiMD by registering to expand it. |
